Skip to content

Effect of Pulsed Dye Laser on Photodynamic Therapy of Port-Wine Stains

Effect of Pulsed Dye Laser on Photodynamic Therapy of Port-Wine Stains

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036362
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Port Wine Stains

Interventions

pdl treated:pdt treatment
non-treated:pdt treatment

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 1-14 years who met the criteria for diagnosis of port-wine stain in The International Society for the Study of Vascular Anomalies(ISSVA); 2. patients in the untreated group had never received any treatment; 3. patients in the PDL-treated group received at least five 595 nm pulse dye laser (PDL) treatment (Vbeam laser; candela Corp., Boston, MA), The time interval between photodynamic therapy and the last pulse dye laser treatment was at least 3 months; 4. there were complete medical records, standard photos and test records before and after treatment; 5. after fully understanding the treatment plan and risks, patients voluntarily signed the informed consent and was willing to accept clinical trials and cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Original infection, eczema, ulcers in the lesion site; 2. The patient has a history of seizures in the last six months or the condition is not under control; 3. Hypersensitivity to porphyrins, hypersensitivity constitution; 4. scar constitution; 5. A history of heavily UV exposure in the last 3 months; 6. With abnormal electrocardiogram, heart disease, liver damage, pregnancy or other underlying diseases that may affect treatment; 7. Patients are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Clinical efficiency;

Secondary

MeasureTime frame
clearing rate of hyperpigmentation;

Countries

China

Contacts

Public ContactMa Gang

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine

docmagang@126.com+86 13391063602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026